Clinical trials are essential for drug development, yet they frequently face delays due to ineffective site selection, leading to protocol violations, compromised data quality, and soaring costs. In fact, 90% of trials fail to meet their timelines, often due to inadequate staffing and recruitment challenges.
Traditional site selection methods are outdated and inefficient, a problem exacerbated by the COVID-19 pandemic. Leveraging data-driven insights can transform this process by analyzing real-time patient populations, investigator performance, and site capabilities, ensuring trials start on time and stay on track.